Integrity Applications, Inc. (OTCQB: IGAP) has appointed Dr. David C. Klonoff as Chair of its Scientific Advisory Board. Dr. Klonoff, a leading endocrinologist, brings extensive experience in diabetes technology, having led over 120 clinical trials. His role will involve guiding Integrity through critical clinical and regulatory strategies for its GlucoTrack device, a non-invasive glucose monitoring tool. The company is focusing on advancing GlucoTrack's U.S. FDA clinical trials and go-to-market strategy. Integrity aims to leverage Dr. Klonoff's expertise to enhance product development and clinical programs.
Integrity Applications, Inc. (IGAP) provided an operational update for 2020, emphasizing its response to the COVID-19 pandemic and need for digital health solutions for diabetes. The company expanded its management team, reducing debt and completing a $15 million capital raise. A new development plan for the next-generation GlucoTrack (GT 2.0) aims to enhance accuracy and reduce costs. The company is pursuing U.S. market entry and potential FDA trials while progressing with insurance reimbursement in the Netherlands. Integrity Applications remains optimistic about future growth and market opportunities.